Anjali V. Sheahan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anjali V. Sheahan has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Katherine L. Morel
South Australian Immunogenomics Cancer Institute, The University of Adelaide
31 shared publications - Leigh Ellis
Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
31 shared publications - Beatriz German
Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
30 shared publications - Deborah L. Burkhart
Dana-Farber Cancer Institute
30 shared publications - Hannah E. Bergom
3)Department of Medicine, University of Minnesota, Masonic Cancer Center, Minneapolis, MN, USA
30 shared publications - Himisha Beltran
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
30 shared publications
Latest Publications
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplement Figure 2 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
Supplement Figure 2. A. SKO, DKO, and PPKO were cultured as 3-dimensional spheroids and treated with the indicated concentrations of the CDK2 inhibitor - BGG463 over 72 hours. Cell growth was determined by CellTiter-Glo luminescent cell viability assay. B. Western blot analysis for Cdk2, Cdk5, and Vinculin following DKO and PPKO were treated with the indicated concentration of the CDK2 PROTAC - CPS2. Full western blot membranes for C) CDK2, D) CDK5, and E) vinculin.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplement Figure 2 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
Supplement Figure 2. A. SKO, DKO, and PPKO were cultured as 3-dimensional spheroids and treated with the indicated concentrations of the CDK2 inhibitor - BGG463 over 72 hours. Cell growth was determined by CellTiter-Glo luminescent cell viability assay. B. Western blot analysis for Cdk2, Cdk5, and Vinculin following DKO and PPKO were treated with the indicated concentration of the CDK2 PROTAC - CPS2. Full western blot membranes for C) CDK2, D) CDK5, and E) vinculin.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
DEG analysis between DKO Mybl2 KO versus DKO Ctl cells and PPKO Mybl2 KO versus PPKO Ctl
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
DEG analysis between DKO Mybl2 KO versus DKO Ctl cells and PPKO Mybl2 KO versus PPKO Ctl
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
Combined genes enriched in human NEPC, PDX samples and NE-like mouse models
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
Combined genes enriched in human NEPC, PDX samples and NE-like mouse models
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplement Figure 1 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
A. Full membrane following CRISPR targeting of Mybl2 indicating specific targeting of our target gene. B. DKO-Ctl and DKO-Mybl2 KO cells were cultured as 2-dimensional monolayers and overall cell growth was determined by CellTiter-Glo luminescent cell viability assay.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplement Figure 1 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
A. Full membrane following CRISPR targeting of Mybl2 indicating specific targeting of our target gene. B. DKO-Ctl and DKO-Mybl2 KO cells were cultured as 2-dimensional monolayers and overall cell growth was determined by CellTiter-Glo luminescent cell viability assay.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
Summary of Peak calls following H3K27ac ChIPseq with Atacseq integration.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
Summary of Peak calls following H3K27ac ChIPseq with Atacseq integration.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
Inhibition of CDK2 represents a novel therapeutic target for NEPC. A, Tumoral growth curve of murine DKO cells in C57BL/6N and (B) PPKO cells in C57BL/6N mice and treated with either vehicle control or the CDK2 PROTAC—CPS2. Mice were treated every 7 days (D7 and D14) with CPS2 (400 mg/kg) by intraperitoneal injection. Tumor growth was monitored every second day for 16 days (D16) by serial caliper measurements. Tumoral weight was measured at D16 after dissection (n = 5 mice per treatment group (±1 SEM). C, Immunofluorescent IHC staining for CDK2 in DKO and (D) PPKO tumors show that CPS2 inhibition significantly reduces CDK2 expression. E and F, Example pictures of hematoxylin and eosin, Ki67, and p-γH2AX IHC staining in murine DKO and PPKO tumors from the in vivo study and corresponding quantification of the percentage of positive nuclei from total cells (n = 5 mice per treatment group, ±1 SEM).
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
Inhibition of CDK2 represents a novel therapeutic target for NEPC. A, Tumoral growth curve of murine DKO cells in C57BL/6N and (B) PPKO cells in C57BL/6N mice and treated with either vehicle control or the CDK2 PROTAC—CPS2. Mice were treated every 7 days (D7 and D14) with CPS2 (400 mg/kg) by intraperitoneal injection. Tumor growth was monitored every second day for 16 days (D16) by serial caliper measurements. Tumoral weight was measured at D16 after dissection (n = 5 mice per treatment group (±1 SEM). C, Immunofluorescent IHC staining for CDK2 in DKO and (D) PPKO tumors show that CPS2 inhibition significantly reduces CDK2 expression. E and F, Example pictures of hematoxylin and eosin, Ki67, and p-γH2AX IHC staining in murine DKO and PPKO tumors from the in vivo study and corresponding quantification of the percentage of positive nuclei from total cells (n = 5 mice per treatment group, ±1 SEM).
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
Mybl2 is a genetic dependency associated with CDK2 expression in NEPC. A, Tumoral growth curve of murine DKO Ctl and DKO Mybl2 KO cells and (B) PPKO Ctl cells and PPKO Mybl2 KO cells in NOD SCID mice. Tumor growth was monitored by serial caliper measurements every second day for 16 days (D16). Tumor weight was measured at D16 after dissection (n = 5 mice per treatment group (±1 SEM). C, Top responses from the cancer therapeutics response portal analysis using a MYBL2 gene signature. DEMETER gene dependency of CDK family members 2, 5, and 7 across human prostate cancer cell lines indicating as significant, as outlined in Fig. 3A. D, Box plot graphs summarizing the RNA-seq analysis from published prostate cancer GEMMs (first and second graphs, including wild-type, SKO, DKO, NP:Nkx3.1CreERT2:Ptenf/f and NPp53:Nkx3.1CreERT2:Ptenf/f:Trp53f/f), and human samples (third graph, including CRPC and NEPC samples) indicate CDK2 upregulation in NEPC mouse models and human patients. E, Immunofluorescent IHC staining for CDK2 in DKO and (F) PPKO murine tumors indicates a significant loss of CDK2 expression following MYBL2 KO.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
Mybl2 is a genetic dependency associated with CDK2 expression in NEPC. A, Tumoral growth curve of murine DKO Ctl and DKO Mybl2 KO cells and (B) PPKO Ctl cells and PPKO Mybl2 KO cells in NOD SCID mice. Tumor growth was monitored by serial caliper measurements every second day for 16 days (D16). Tumor weight was measured at D16 after dissection (n = 5 mice per treatment group (±1 SEM). C, Top responses from the cancer therapeutics response portal analysis using a MYBL2 gene signature. DEMETER gene dependency of CDK family members 2, 5, and 7 across human prostate cancer cell lines indicating as significant, as outlined in Fig. 3A. D, Box plot graphs summarizing the RNA-seq analysis from published prostate cancer GEMMs (first and second graphs, including wild-type, SKO, DKO, NP:Nkx3.1CreERT2:Ptenf/f and NPp53:Nkx3.1CreERT2:Ptenf/f:Trp53f/f), and human samples (third graph, including CRPC and NEPC samples) indicate CDK2 upregulation in NEPC mouse models and human patients. E, Immunofluorescent IHC staining for CDK2 in DKO and (F) PPKO murine tumors indicates a significant loss of CDK2 expression following MYBL2 KO.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
MYBL2 expression and activity is enriched in human NEPC and NE-like mouse models. A, Venn diagram integrating the differential gene expression (DEG) list from PBCre4:Ptenf/f (SKO) vs. PBCre4:Ptenf/f:Rb1f/f (DKO) mouse models, human NEPC vs. adenocarcinoma samples, and patient-derived xenografts of LuCaP obtained from human patients with NEPC vs. patients with adenocarcinoma shows that the three independent datasets shared 1,516 genes (left). GSEA of the 1,516 shared genes indicates that the fischer_dream_targets genes may be involved in the regulation of CRPC-AI development (right). All the pathways listed are statistically significant with P < 0.05. B, Bar and box plot summarizing the MYBL2 expression level in human patients with prostate cancer at different stages of the disease progression. C, Correlation analysis mouse and (D) human samples indicate that enrichment of MYBL2 transcriptional function is highly associated with NE and ESC gene signatures in NEPC models and patient samples compared with their adenocarcinoma counterparts. WT, wild type.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
MYBL2 expression and activity is enriched in human NEPC and NE-like mouse models. A, Venn diagram integrating the differential gene expression (DEG) list from PBCre4:Ptenf/f (SKO) vs. PBCre4:Ptenf/f:Rb1f/f (DKO) mouse models, human NEPC vs. adenocarcinoma samples, and patient-derived xenografts of LuCaP obtained from human patients with NEPC vs. patients with adenocarcinoma shows that the three independent datasets shared 1,516 genes (left). GSEA of the 1,516 shared genes indicates that the fischer_dream_targets genes may be involved in the regulation of CRPC-AI development (right). All the pathways listed are statistically significant with P < 0.05. B, Bar and box plot summarizing the MYBL2 expression level in human patients with prostate cancer at different stages of the disease progression. C, Correlation analysis mouse and (D) human samples indicate that enrichment of MYBL2 transcriptional function is highly associated with NE and ESC gene signatures in NEPC models and patient samples compared with their adenocarcinoma counterparts. WT, wild type.
- Open Access
- 2 September 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
DEG analysis between DKO Mybl2 KO versus DKO Ctl cells and PPKO Mybl2 KO versus PPKO Ctl
- 2 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
DEG analysis between DKO Mybl2 KO versus DKO Ctl cells and PPKO Mybl2 KO versus PPKO Ctl
- Open Access
- 2 September 2024
- Published by American Association for Cancer Research (AACR)
Figure 6 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
Inhibition of CDK2 represents a novel therapeutic target for NEPC. A, Tumoral growth curve of murine DKO cells in C57BL/6N and (B) PPKO cells in C57BL/6N mice and treated with either vehicle control or the CDK2 PROTAC—CPS2. Mice were treated every 7 days (D7 and D14) with CPS2 (400 mg/kg) by intraperitoneal injection. Tumor growth was monitored every second day for 16 days (D16) by serial caliper measurements. Tumoral weight was measured at D16 after dissection (n = 5 mice per treatment group (±1 SEM). C, Immunofluorescent IHC staining for CDK2 in DKO and (D) PPKO tumors show that CPS2 inhibition significantly reduces CDK2 expression. E and F, Example pictures of hematoxylin and eosin, Ki67, and p-γH2AX IHC staining in murine DKO and PPKO tumors from the in vivo study and corresponding quantification of the percentage of positive nuclei from total cells (n = 5 mice per treatment group, ±1 SEM).
- 2 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer
Inhibition of CDK2 represents a novel therapeutic target for NEPC. A, Tumoral growth curve of murine DKO cells in C57BL/6N and (B) PPKO cells in C57BL/6N mice and treated with either vehicle control or the CDK2 PROTAC—CPS2. Mice were treated every 7 days (D7 and D14) with CPS2 (400 mg/kg) by intraperitoneal injection. Tumor growth was monitored every second day for 16 days (D16) by serial caliper measurements. Tumoral weight was measured at D16 after dissection (n = 5 mice per treatment group (±1 SEM). C, Immunofluorescent IHC staining for CDK2 in DKO and (D) PPKO tumors show that CPS2 inhibition significantly reduces CDK2 expression. E and F, Example pictures of hematoxylin and eosin, Ki67, and p-γH2AX IHC staining in murine DKO and PPKO tumors from the in vivo study and corresponding quantification of the percentage of positive nuclei from total cells (n = 5 mice per treatment group, ±1 SEM).